Drug

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition
GDK BiotechnologyProduct approvals

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

Jiangsu GDK Biotechnology Co., Ltd. (SHA: 688670) announced that it has received a Drug Registration Certificate from the National Medical Products Administration (NMPA) for its trivalent influenza split vaccine (Injection,…

FDA Approves Genentech's Tecentriq for Adjuvant Treatment of dMMR Colon Cancer – Landmark ATOMIC Trial Shows 50% Risk Reduction

FDA Approves Genentech’s Tecentriq for Adjuvant Treatment of dMMR Colon Cancer – Landmark ATOMIC Trial Shows 50% Risk Reduction

Taienkang Pharma Subsidiary HABKSON Wins NMPA Approval for Diquafosol Sodium Eye Drops – Generic Dry Eye Therapy Enters RMB 228 Million Chinese Ophthalmic Market

Taienkang Pharma Subsidiary HABKSON Wins NMPA Approval for Diquafosol Sodium Eye Drops – Generic Dry Eye Therapy Enters RMB 228 Million Chinese Ophthalmic Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial approval / initiationDiabetes

Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes

Hot targetsHuadong Medicine

Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication

CancerClinical trial results

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Clinical trial approval / initiationGastroenterology

Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori

Show More